

AWARD NUMBER: W81XWH-16-1-0300

TITLE: Metformin Therapy for Fanconis Anemia

PRINCIPAL INVESTIGATOR: Markus Grompe

CONTRACTING ORGANIZATION: Oregon Health & Science University
Portland OR 97239

REPORT DATE: August 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE August 2017		2. REPORT TYPE Annual		3. DATES COVERED 1 Aug 2016 - 31 Jul 2017	
4. TITLE AND SUBTITLE Metformin Therapy for Fanconis Anemia				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0300	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Markus Grompe E-Mail: grompem@ohsu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oregon Health & Science University 3181 SW Sam Jackson Park Rd Mailcode: L106OPAM Portland, OR 97239-3098				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This award pertains to the treatment of the inherited bone marrow failure syndrome Fanconi's Anemia. Specifically, the commonly used diabetes drug metformin will be tested by itself and in combination with the current standard of care, anabolic steroids.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	5
5. Changes/Problems.....	5
6. Products.....	5
7. Participants & Other Collaborating Organizations.....	6
8. Special Reporting Requirements.....	7
9. Appendices.....	7

1. Introduction

This award pertains to the treatment of the inherited bone marrow failure syndrome Fanconi's Anemia. Specifically, the commonly used diabetes drug metformin will be tested by itself and in combination with the current standard of care, anabolic steroids.

2. Keywords

Fanconi Anemia, bone marrow failure, treatment, drug, small molecule, DNA damage, metformin

3. Accomplishments

We started work on this project less than a year ago and already have made good progress.

Major Goals:

Specific Aim 1: To evaluate metformin for the treatment of FA

Metformin is a biguanide drug widely used for the treatment of type 2 diabetes. In humans, it is known to have cancer chemoprevention properties. We found that MET enhances hematopoiesis specifically in *Fancd2*^{-/-} mice, but how it does so is unclear. Here, we will determine whether MET acts via AMPK activation or as an aldehyde scavenger. We will ascertain whether it can prevent inflammation-induced anemia and whether it is beneficial when BMF has already started.

Specific Aim 2: To evaluate the combination of anabolic androgens with metformin for the treatment of FA.

Many FA patients respond to androgens by significant improvement of their blood counts⁸. We now understand how androgens work and predict that there is no overlap with the mechanism of action of MET. Androgen therapy does not cure FA and we will therefore determine whether the combination of oxymetholone with metformin can synergistically improve hematopoiesis in FA.

Goals achieved:

Specific progress has been made on both Aims.

For Aim 1, we have generated a cohort of *Fancd2* mutant mice to be aged until they display bone marrow failure. We plan to determine whether metformin can reverse already established anemia. Anemia developments takes 12-18 months from birth and hence the metformin treatment will start at that time, during year 2 of the grant.

We have also started a cohort of *Fancd2/Aldh2* double mutant mice to address the question of whether metformin can directly scavenge aldehydes. In addition, we have generated some human Fanconi cell lines deficient in aldehyde metabolism to perform in vitro experiments in parallel.

Aim 2 has a timeline of over one year and generating the mice required to populate the project took considerable time, but has now been accomplished. We have populated four cohorts of FA mutant mice: 1) Mice receiving both oxymetholone and metformin; 2) mice receiving metformin alone; 3) mice receiving oxymetholone alone and 4) controls, receiving placebo (no drug). The experiments are ongoing. No overt side effects of the combination therapy have been seen.

Training opportunities:

Nothing to report.

Results dissemination:

Nothing to report.

Plans for the next reporting period:

We are pretty much on track of the timeline described in our application. A lot of experimental animals need to be generated by breeding and then aged from 6-18 months. Breeding efficiencies are only $\frac{1}{4}$ (recessive disease) and populating our study cohorts simply takes time. Hence, most of the experimental readouts will come in year 2 of the grant. We will complete Aim 2 and do a comprehensive analysis of the hematopoietic effects of combination therapy. The long term treatment will continue for another 9 months before analysis takes place. For completion of Aim 1, we need to generate a cohort of FA mice with already established bone marrow failure. These mice have been generated and now simply have to be aged. Despite our finding that metformin can in fact detoxify aldehydes, we will nonetheless complete our experiments aimed as assessing the role of AMPK activation.

4. Impact**Principal discipline:**

Metformin has never been considered for the treatment of bone marrow failure before. Our preclinical data in mice are sufficiently compelling that a clinical trial of children with Fanconi Anemia with metformin is being implemented at Boston Childrens Hospital. The planned start date is January 2018.

Other disciplines:

Although hundreds of papers have been written about metformin and although many cancer prevention clinical trials are ongoing, metformin has never before been reported to block DNA damage and enhance genome integrity. The aldehyde scavenging effects of metformin have also not been previously reported. We believe that our findings provide a potential mechanism for the cancer prevention effects of metformin. This is a novel paradigm in the field.

Technology transfer:

Nothing to report.

Society:

Nothing to report.

5. Changes

Nothing to report.

We are happy to report that our experimental plans are coming off without a hitch and are on time.

6. Products

Spanish Fanconi Anemia Society Meeting, Madrid, Spain, June 2017: "Small Molecule Therapy of Fanconi Anemia". Author: M. Grompe

Web-sites:
Nothing to report

Technologies:
Nothing to report

Inventions/patents:
Nothing to report

7. Participants and other collaborating organizations.

Individuals on the project

<i>Name</i>	<i>Markus Grompe, M.D.</i>
<i>Project Role</i>	<i>Principal investigator</i>
<i>Researcher ID</i>	<i>0000-0002-6616-4345</i>
<i>Person month worked</i>	<i>1</i>
<i>Contribution</i>	<i>Overall experimental design. Oversight of project personnel; communication with funding agencies; manuscript writing.</i>
<i>Funding support</i>	
<i>Name</i>	<i>Qingshuo Zhang, Ph.D.</i>
<i>Project Role</i>	<i>Senior Research Associate</i>
<i>Researcher ID</i>	
<i>Person month worked</i>	<i>9</i>
<i>Contribution</i>	<i>Dr. Zhang is the project leader in the lab; He designs most experiments (in collaboration with Dr. Grompe), performs experimentation himself, collects data and oversees the research assistants working on the project.</i>
<i>Funding support</i>	
<i>Name</i>	<i>Leslie Wakefield</i>
<i>Project Role</i>	<i>Research Assistant</i>
<i>Researcher ID</i>	
<i>Person month worked</i>	<i>3</i>
<i>Contribution</i>	<i>Ms. Wakefield is in charge of our mouse animal colony (breeding, genotyping etc.) and assists Dr. Zhang with hands on experimentation.</i>
<i>Funding support</i>	

<i>Name</i>	<i>Sean Nygaard</i>
<i>Project Role</i>	<i>Laboratory Manager</i>
<i>Researcher ID</i>	
<i>Person month worked</i>	<i>1</i>
<i>Contribution</i>	<i>Mr. Nygaard is in charge of overall lab organization, including order supplies, equipment maintenance, compliance (animal care).</i>
<i>Funding support</i>	

*Changes:
Nothing to report*

*Other organizations:
Nothing to report.*

8. Special Reporting Requirements

Nothing to report.

9. Appendices

Nothing to report